

## **Inova and BIO, in partnership with Evaluate, announce a new series of therapeutic-specific Virtual Partnering events for 2021**

These events will bring together early-stage biotechs and reputed biopharma enabling focused meetings.

### **9 February 2021:**

**Inova** and the **Biotechnology Innovation Organization (BIO)**, in partnership with **Evaluate** announce the second annual series of Virtual Partnering events focused on critical therapeutic areas with great unmet need – oncology, immunology, and neuroscience.

Four events will be held across 2021:

- Virtual Partnering Oncology (2-5 March)
- Virtual Partnering Immunology (9-12 March)
- Virtual Partnering Oncology (28 September-1 October)
- Virtual Partnering Neuroscience (5-8 October)

In 2020 thousands of attendees were welcomed to Virtual Partnering events focused on COVID-19, oncology, neuroscience, and infectious disease. Hundreds of early-stage biotechs met with pharmaceutical companies, including many of the Top 50 pharma firms. Attendees welcomed the opportunity to meet virtually, praised Inova's partnering platform as "efficient and user friendly" and "best in class", and identified the capacity to meet "relevant companies", schedule "several rapid meetings in a few days" and "generate real interest in our programs" among the benefits of participating in a virtual partnering event.

### **Spring Events**

- **Virtual Partnering Oncology** welcomes early-stage biotechs with innovative therapies targeting cancers, including chemotherapy, small molecule and oral drug formulations, cancer vaccines, immune cell therapies, cytokine modulation and monoclonal antibodies. These early-stage biotechs will be joined by pharmaceutical companies seeking partnerships, investors seeking innovative therapies, and life science companies searching for clinical trial partnerships.
- **Virtual Partnering Immunology** welcomes early-stage biotechs focused on therapeutic areas including rheumatology, dermatology, gastroenterology, inflammatory and autoimmune diseases. With new science addressing autoimmune conditions including tailoring treatments to complement the heterogenous pathophysiologic mechanisms to each patient, these early-stage biotechs can expect interest from the large pharmaceutical companies that rely on virtual partnering events to fill their immunology pipeline.

### **Accelerating Partnering, Getting to Market Faster,**

Inova, BIO and Evaluate understand the importance of connecting early-stage biotechs with established pharma companies to accelerate partnering efforts and bring new therapies to market faster.

**Gilles Toulemonde**, Inova CEO and co-founder, said: "Accelerating partnering for the future of medicine is core to our mission at Inova. After our initial series of virtual partnering events in 2020, I'm looking forward to our events powering further success for early-stage biotechs seeking partners in oncology, immunology, and neuroscience in 2021."

**Dr Michelle McMurry-Heath**, President and CEO at BIO, said: "Early-stage biotech companies are working to solve some of the most complex scientific challenges today and are breaking new ground in advancing life-saving treatments in oncology, immunology, and neuroscience. Getting these advances to the market faster requires finding the right partners, and that's exactly what this virtual partnering series facilitates."

**Deborah Kobewka, Evaluate CEO**, said: "Partnerships and collaboration are the lifeblood of biopharma, combining innovative drug technologies with the expertise and resources needed to realize their full potential. We're delighted to support these important virtual events and share new knowledge and insights to facilitate productive partnering discussions."

Registration is now open for Virtual Partnering Oncology and Immunology at <https://virtual-partnering.com>

#### **Media contacts**

##### **Inova**

Sabrina Buquoy

[sabrina.buquoy@inova-software.com](mailto:sabrina.buquoy@inova-software.com)

##### **BIO**

Theresa Brady

[tbrady@bio.org](mailto:tbrady@bio.org)

##### **Evaluate**

Jennifer Dinkel

[jennifer.dinkel@evaluate.com](mailto:jennifer.dinkel@evaluate.com)

\*\*

#### **About Inova**

Inova accelerates partnering for the future of medicine. Over 150 life science companies, including 50% of the top 50 pharmaceutical companies already use Inova's cloud platform. They secure licensing and collaboration opportunities, accelerate deal making and successfully manage their alliances. Inova also provides One-on-One Partnering™, the market leading partnering & matchmaking platform that facilitates thousands of face-to-face meetings at dozens of biopharma conferences worldwide including the BIO International Convention and BIO Asia. For instance, in the weeks before the BIO International Convention, 4,000 biopharma companies connect online, list their technologies and capabilities, and request meetings with potential partners. By the time the Convention opens thousands of relevant meetings are scheduled – almost 50,000 at BIO Convention 2019 alone.

For more information visit: <https://www.inova-software.com/>

Follow us on Twitter @Inova\_Software

Find us on [LinkedIn](#)

#### **About BIO**

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial

and environmental biotechnology products. BIO also produces the [BIO International Convention](#), the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

For more information visit: <https://www.bio.org/>

Follow us on Twitter @IAmBiotech

Find us on [LinkedIn](#)

### **About Evaluate**

Evaluate provides trusted commercial intelligence and predictive analytics for the pharmaceutical industry and their advisors. Our Evaluate Omnium and EvaluatePharma® platforms offer unique and dynamic insights into pharma asset risk and commercial potential alongside a seamless, comprehensive view of the pharmaceutical market landscape. Evaluate Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into current and future industry developments.

Evaluate has been a partner to industry-leading organisations for 25 years. For more information on how we give our clients the time and understanding to drive better decisions, visit [www.evaluate.com](http://www.evaluate.com).

Follow us on Twitter: @EvaluatePharma, @EvaluateVantage